Toni Choueiri: New insights from the JAVELIN Renal 101 trial in RCC in Cancer Discovery
Toni Choueiri, Professor of Medicine at Harvard Medical School and Director of the Lank Center for Genitourinary Oncology at the Dana–Farber Cancer Institute, shared a post on X/Twitter:
“JUST IN: New insights from the JAVELIN Renal 101 trial in RCC in Cancer Discovery. We delve into integrative biomarkers of PDL1 inhibitor avelumab + TKI axitinib (A+Ax) vs. TKI sunitinib (Sun).
As a reminder, the phase 3 JR101 trial showed improved PFS for aRCC patients treated with A+Ax vs. Sun. Final OS pending –last update ESMO Open with John Haanen The Netherlands Cancer Institute leading
In a previous report in Nature Medicine led by Robert Motzer, we examined immune + angiogenic gene expression signatures, as well as somatic alterations. We highlighted the role of NK-mediated cytotoxicity + prognostic implications of double mutants.
In this work, we present the results of COMPREHENSIVE analyses of the JR101 data (circulating proteins, cell populations, and TCR repertoires…). We evaluated the association with patient outcomes in light of pretreatment tumor attributes, such as the occurrence of tumor-infiltrating leukocytes and tumor genotype.
Different peripheral cell populations were associated with PFS in each arm: High PFS was associated with high lymphocyte (w/ Sun) and low monocytes (w/ A+Ax) Moreover, blood cell levels exhibited little change during A+Ax treatment, but fluctuated with Sun dosing schedule.
Baseline T-cell quantity and repertoire in peripheral blood correlated with longer PFS w/ Sun, not A+Ax. While expanded peripheral T-cells were seen w/ Sun, A+Ax showed greater TCR repertoire modulation.
Source: Toni Choueiri/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023